Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW
APOPW was delisted on the 3rd of August, 2021.
1 hedge funds and large institutions have $22K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2017 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
95% less capital invested
Capital invested by funds: $403K → $22K (-$381K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$346K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $22K | -$29.1K | -12,577 | -55% |
|
|
AFM
2
Anson Funds Management
Dallas,
Texas
| – | -$346K | -40,239 | Closed |
|
APOPW Hedge Fund Activity: Q2 2017 in Review
1 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q2 2017, worth a combined $22K — down 95% from $403K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of APOPW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Anson Funds Management, exiting entirely with an estimated $346K sold.
- 1 institutional investor held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q2 2017, down from 2 in Q1 2017.
- Funds reported $22K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q2 2017, down 95% quarter-over-quarter.
- 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q2 2017 and 1 closed out, a net change of -1 holder.
- The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs seller in Q2 2017 was Anson Funds Management, an estimated $346K sold.
Based on aggregated 13F filings for Q2 2017.